Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) that is revolutionizing cancer treatment by using mini-protein therapeutics to directly inhibit MYC, a central engine for cancer proliferation, survival, and resistance to treatment
Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) that is revolutionizing cancer treatment by using mini-protein therapeutics to directly inhibit MYC, a central engine for cancer proliferation, survival, and resistance to treatment. Their first-in-class MYC inhibitor, OMO-103, aims to improve survival and quality of life for cancer patients with abnormal MYC activity.